![Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real-world clinical practice: a multicenter retrospective clinical study | International Journal of Clinical Oncology Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real-world clinical practice: a multicenter retrospective clinical study | International Journal of Clinical Oncology](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs10147-020-01829-0/MediaObjects/10147_2020_1829_Fig3_HTML.png)
Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real-world clinical practice: a multicenter retrospective clinical study | International Journal of Clinical Oncology
![A) Overall response rate by cohorts. ORR indicates a response of PR or... | Download Scientific Diagram A) Overall response rate by cohorts. ORR indicates a response of PR or... | Download Scientific Diagram](https://www.researchgate.net/publication/348022825/figure/fig1/AS:11431281173673712@1689003069941/A-Overall-response-rate-by-cohorts-ORR-indicates-a-response-of-PR-or-better-ORR.png)
A) Overall response rate by cohorts. ORR indicates a response of PR or... | Download Scientific Diagram
Response rates and minimal residual disease outcomes as potential surrogates for progression-free survival in newly diagnosed multiple myeloma | PLOS ONE
![Exploring the relationship between Overall Survival (OS), Progression Free Survival (PFS) and Objective Response Rate (ORR) in patients with advanced melanoma - ScienceDirect Exploring the relationship between Overall Survival (OS), Progression Free Survival (PFS) and Objective Response Rate (ORR) in patients with advanced melanoma - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2468294220301076-gr1.jpg)
Exploring the relationship between Overall Survival (OS), Progression Free Survival (PFS) and Objective Response Rate (ORR) in patients with advanced melanoma - ScienceDirect
![Updated Data for Indoximod Plus KEYTRUDA® (pembrolizumab) Demonstrate Improvement of Response Rate for Patients with Advanced Melanoma | Business Wire Updated Data for Indoximod Plus KEYTRUDA® (pembrolizumab) Demonstrate Improvement of Response Rate for Patients with Advanced Melanoma | Business Wire](https://mms.businesswire.com/media/20170907005441/en/610835/5/Melanoma_Data_Chart_.jpg)
Updated Data for Indoximod Plus KEYTRUDA® (pembrolizumab) Demonstrate Improvement of Response Rate for Patients with Advanced Melanoma | Business Wire
![Objective response rate is a possible surrogate endpoint for survival in patients with advanced, recurrent ovarian cancer - ScienceDirect Objective response rate is a possible surrogate endpoint for survival in patients with advanced, recurrent ovarian cancer - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0090825817307709-gr3.jpg)